INT178237

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2004
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 18
Disease Relevance 8.56
Pain Relevance 0.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plaque 2
erythrocytes 1
bone marrow 1
lung 1
egg 1
Vhl-ps1 (Mus musculus)
Pain Link Frequency Relevance Heat
tolerance 30 99.66 Very High Very High Very High
cytokine 77 74.96 Quite High
cva 3 70.64 Quite High
Inflammatory response 4 63.12 Quite High
anesthesia 18 56.72 Quite High
Inflammation 9 14.72 Low Low
chemokine 9 7.84 Low Low
ketamine 27 5.00 Very Low Very Low Very Low
addiction 9 5.00 Very Low Very Low Very Low
imagery 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Influenza Virus Infection 870 100.00 Very High Very High Very High
Stress 14 99.92 Very High Very High Very High
Immunization 182 99.66 Very High Very High Very High
Injury 80 99.64 Very High Very High Very High
Targeted Disruption 57 98.96 Very High Very High Very High
Nephrotoxicity 4 97.44 Very High Very High Very High
Sprains And Strains 87 85.76 High High
Death 57 84.72 Quite High
Infection 242 84.44 Quite High
Disease 95 76.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
H5N1 VLP-immunized mice showed significantly higher numbers of IFN-?
Gene_expression (showed) of VLP
1) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2646145 Disease Relevance 0.28 Pain Relevance 0.07
H5N1 VLP preparations hemagglutinated chicken erythrocytes with titers ?
Gene_expression (preparations) of VLP in erythrocytes
2) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2646145 Disease Relevance 0.66 Pain Relevance 0
Significant levels of H5 virus specific IgG antibodies were induced in nasal and tracheal washes as well as in lung extracts of mice after prime-boost immunization with H5N1 VLPs (H5VLP group in Fig. 8A).
Gene_expression (group) of H5VLP in lung associated with immunization
3) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2646145 Disease Relevance 0.18 Pain Relevance 0
Significant numbers of virus-specific antibody secreting bone marrow cells were noted from H5N1 VLP-immunized mice but not from PBS control mice within 18 hr in culture, suggesting that pre-existing plasma cells induced by VLP vaccination were actively secreting antibodies to H5N1 virus antigen (Fig. 7A).
Gene_expression (vaccination) of VLP in bone marrow
4) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2646145 Disease Relevance 0.24 Pain Relevance 0
The HA, NA, and M1 genes for the H5N1 VLP vaccine were synthesized by GeneArt (Germany) based upon sequences ISDN125873, ISDN125875, ISDN125876 [17] and followed by cloning into E. coli bacmids (Fig. 1A), plaque-purification of recombinant baculoviruses with HA, NA, and M1 genes in a single vector and expression in Spodoptera frugiperda Sf9 insect cells (ATCC CRL-1711) as previously described [14].
Gene_expression (synthesized) of VLP in plaque
5) Confidence 0.36 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.06 Pain Relevance 0
At 72 h post-transfection, cells were harvested for VLP production and recovery of recombinant baculoviruses in the culture medium.
Gene_expression (production) of VLP
6) Confidence 0.36 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.06 Pain Relevance 0
Recently, our group described the development of influenza A H3N2 and H9N2 VLP vaccines comprised of only three influenza virus proteins, hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) [14], [15] expressed in insect cells.
Gene_expression (expressed) of VLP associated with influenza virus infection
7) Confidence 0.36 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.83 Pain Relevance 0
Surprisingly, there was little change in the dissociation rate of VLP elicited antibodies when tested against the heterologous Viet Nam clade 1 HA antigen (3.01×10?
Gene_expression (antibodies) of VLP
8) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.07 Pain Relevance 0
This is the first report of an H5N1 VLP vaccine derived from a clade 2 influenza isolate.
Gene_expression (vaccine) of VLP associated with influenza virus infection
9) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.32 Pain Relevance 0
The HA, NA, and M1 genes for the H5N1 VLP vaccine were synthesized by GeneArt (Germany) based upon sequences ISDN125873, ISDN125875, ISDN125876 [17] and followed by cloning into E. coli bacmids (Fig. 1A), plaque-purification of recombinant baculoviruses with HA, NA, and M1 genes in a single vector and expression in Spodoptera frugiperda Sf9 insect cells (ATCC CRL-1711) as previously described [14].
Gene_expression (expression) of VLP in plaque
10) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.06 Pain Relevance 0
These data argue that self-tolerance may exist in the APP transgenic mice, and that this self-tolerance can be overcome using the VLP-A?
Gene_expression (using) of VLP associated with targeted disruption and tolerance
11) Confidence 0.28 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC442125 Disease Relevance 0.49 Pain Relevance 0.10
l VLP preparation containing 5.6 ?
Gene_expression (preparation) of VLP
12) Confidence 0.28 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC442125 Disease Relevance 0.34 Pain Relevance 0.06
in APP Tg mice, and whether VLP conjugation could overcome tolerance, we compared the ability to induce anti-A?
Gene_expression (conjugation) of VLP associated with tolerance
13) Confidence 0.28 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC442125 Disease Relevance 0.82 Pain Relevance 0.25
These influenza VLP vaccines do not require the use of any live influenza virus during the development, manufacturing, or administration of these vaccines.
Gene_expression (vaccines) of VLP associated with influenza virus infection
14) Confidence 0.27 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.88 Pain Relevance 0
Results presented in this report indicate that our A/Indonesia/05/2005 (clade 2) VLP vaccine elicited higher HAI antibody titers than the A/Viet Nam/1203/2004 (clade 1) VLP vaccine without the use an adjuvant and elicited a robust and broadly reactive immune response following two vaccinations.
Gene_expression (vaccine) of VLP
15) Confidence 0.27 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.29 Pain Relevance 0
As an alternative to conventional egg-based and mammalian cell-produced influenza vaccine approaches, these recombinant-based VLP vaccines are produced with a baculovirus system, which is a promising, innovative technology for efficient, safe, high-yielding and low-cost commercial vaccines for influenza virus.
Gene_expression (produced) of VLP in egg associated with influenza virus infection
16) Confidence 0.25 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2200794 Disease Relevance 0.89 Pain Relevance 0
Oxidative stress in VLP-treated and non-treated AKI mice
Gene_expression (treated) of VLP associated with stress and injury
17) Confidence 0.12 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2515219 Disease Relevance 1.02 Pain Relevance 0.03
Oxidative stress in VLP-treated and non-treated AKI mice
Gene_expression (non) of VLP associated with stress and injury
18) Confidence 0.12 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2515219 Disease Relevance 1.08 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox